3.37
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.42
Aprire:
$3.4
Volume 24 ore:
140.44K
Relative Volume:
0.59
Capitalizzazione di mercato:
$134.13M
Reddito:
$2.70M
Utile/perdita netta:
$5.53M
Rapporto P/E:
30.64
EPS:
0.11
Flusso di cassa netto:
$-10.55M
1 W Prestazione:
-0.59%
1M Prestazione:
+19.93%
6M Prestazione:
+58.22%
1 anno Prestazione:
+53.18%
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
Nome
Oramed Pharmaceuticals Inc
Settore
Industria
Telefono
646-844-1164
Indirizzo
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Confronta ORMP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
ORMP
Oramed Pharmaceuticals Inc
|
3.37 | 136.12M | 2.70M | 5.53M | -10.55M | 0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.45 | 78.77B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
840.50 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.06 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.38 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-01-12 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-02-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-04-20 | Iniziato | Canaccord Genuity | Buy |
| 2021-02-09 | Iniziato | National Securities | Buy |
| 2020-12-03 | Iniziato | Alliance Global Partners | Buy |
| 2020-03-11 | Iniziato | Aegis Capital | Buy |
| 2019-09-11 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-12-11 | Ripresa | B. Riley FBR, Inc. | Buy |
| 2016-05-26 | Reiterato | FBR Capital | Outperform |
| 2015-12-01 | Reiterato | H.C. Wainwright | Buy |
| 2015-11-19 | Iniziato | FBR Capital | Outperform |
| 2015-04-13 | Ripresa | MLV & Co | Buy |
| 2014-01-30 | Reiterato | Aegis Capital | Buy |
| 2014-01-08 | Reiterato | Aegis Capital | Buy |
| 2014-01-08 | Iniziato | MLV & Co | Buy |
| 2013-12-03 | Iniziato | Aegis Capital | Buy |
Mostra tutto
Oramed Pharmaceuticals Inc Borsa (ORMP) Ultime notizie
Aug Update: What is ReTo Eco Solutions Incs book value per shareJuly 2025 Momentum & Community Consensus Trade Signals - baoquankhu1.vn
Is Oramed Pharmaceuticals Inc. stock a smart retirement pickJuly 2025 Short Interest & Trade Opportunity Analysis Reports - mfd.ru
Portfolio Recap: Should I set a stop loss on SDOWJuly 2025 Fed Impact & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Pass Above Fifty Day Moving AverageTime to Sell? - MarketBeat
Jobs Data: Is Oramed Pharmaceuticals Inc stock good for income investors2025 Historical Comparison & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Oramed Shares Face Pressure Amid Strategic Pivot and Dividend Focus - AD HOC NEWS
Oramed Pharm completes warrant sale, boosting liquidity - MSN
Is Oramed Pharmaceuticals Inc. stock undervalued right nowVolume Analysis Techniques & Plan Every Trade With Controlled Risk - bollywoodhelpline.com
What hedge funds are buying Oramed Pharmaceuticals Inc.Recession Risk & Daily Technical Forecast Reports - bollywoodhelpline.com
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Sees Large Increase in Short Interest - MarketBeat
Published on: 2026-01-17 10:34:33 - baoquankhu1.vn
Oramed Pharmaceuticals Inc.: - marketscreener.com
Oramed Pharm pivots with Lifeward strategic platform deal - TipRanks
Oramed Pharmaceuticals Signs Multiple Material Agreements - TradingView — Track All Markets
3 Promising Penny Stocks With Market Caps Under $200M - simplywall.st
Oramed to transfer oral drug delivery platform to Lifeward By Investing.com - Investing.com Nigeria
Lifeward to acquire Oramed’s oral protein delivery tech in $47 million deal - Investing.com Nigeria
Buyout Rumor: Can Oramed Pharmaceuticals Inc maintain sales growthQuarterly Investment Review & Growth-Oriented Investment Plans - baoquankhu1.vn
Oramed And Lifeward Reveal Strategic Deal - Pulse 2.0
Oramed to transfer oral drug delivery platform to Lifeward - Investing.com India
Lifeward to acquire Oramed’s oral protein delivery tech in $47 million deal By Investing.com - Investing.com South Africa
Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company - manilatimes.net
Oramed and Lifeward Announce Strategic Transaction - Financial Times
Upcoming Events - FinancialContent
Lifeward Ltd. announced that it expects to receive $20 million in funding from Oramed Pharmaceuticals Inc. - marketscreener.com
Oramed Announces Shareholder Capital Return Following Strategic Windfall - AD HOC NEWS
Take Profit: Will Oramed Pharmaceuticals Inc. stock outperform value stocksJuly 2025 Intraday Action & Growth Focused Investment Plans - Улправда
Why Oramed Pharmaceuticals Inc. stock could outperform in 2025Trade Performance Summary & Risk Managed Investment Entry Signals - Улправда
Is Oramed Pharmaceuticals Inc. stock a buy in volatile markets2025 Retail Activity & Daily Volume Surge Signals - ulpravda.ru
Will Oramed Pharmaceuticals Inc. stock outperform value stocks2025 Key Lessons & Intraday High Probability Alerts - ulpravda.ru
Oramed Pharmaceuticals Inc. Declares Dividend of $0.25 (NASDAQ:ORMP) - MarketBeat
Oramed inks deal with Medicox for oral insulin in South Korea - The Pharma Letter
Is Oramed Pharmaceuticals Inc. (OJU1) stock suitable for passive index fundsMarket Sentiment Shifts & Outstanding Capital Returns - Улправда
MSN Money - MSN
Oramed Pharmaceuticals Inc. Approves Cash Dividend Payable on January 26, 2026 - MarketScreener
Oramed stock rises after receiving $18 million payment from Scilex By Investing.com - Investing.com Nigeria
Oramed receives $18 million payment from Scilex, declares dividend By Investing.com - Investing.com Nigeria
Oramed Pharm Announces Dividend After Scilex Payment Gain - TipRanks
Oramed receives $18 million payment from Scilex, declares dividend - Investing.com
Oramed Pharmaceuticals Inc Receives $18 Million Payment and Approves Dividend - TradingView
Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments - Barchart.com
What analysts say about Oramed Pharmaceuticals Inc stockLow Beta Stocks & Breakthrough Profit Margins - earlytimes.in
Oramed Pharm Announces Long-Tenured Director’s Upcoming Resignation - TipRanks
Oramed Pharmaceuticals director Leonard Sank to resign after 18 years By Investing.com - Investing.com Nigeria
Oramed Pharmaceuticals director Leonard Sank to resign after 18 years - Investing.com
Oramed Pharmaceuticals completes $28.5 million warrant repurchase by Scilex - Investing.com Nigeria
Oramed Pharm Completes Warrant Sale, Boosting Liquidity - TipRanks
Oramed Pharmaceuticals Completes Warrant Repurchase with Scilex - TradingView — Track All Markets
Scilex Holding completes $27 million repurchase of warrants from Oramed By Investing.com - Investing.com South Africa
Oramed Pharmaceuticals Inc Azioni (ORMP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):